Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Anderson Website

Stephen K. Anderson, Ph.D.

Portait Photo of Stephen Anderson
Laboratory of Experimental Immunology
Head, Molecular Immunology Group
Senior Investigator (Contr)
Center for Cancer Research
National Cancer Institute
Building 560, Room 31-50
Building 560, Room 31-33 (Lab)
PO Box B
Frederick, MD 21702-1201
Phone:  
301-846-1330
Fax:  
301-846-1673
E-Mail:  
andersonst@mail.nih.gov

Biography

Dr. Stephen Anderson is a senior scientist with Leidos Biomedical Research Inc. working in collaboration with the Laboratory of Experimental Immunology. He obtained his Ph.D. in 1986 from the University of Western Ontario and performed postdoctoral studies on natural killer cells at Mount Sinai Hospital in Toronto. Dr. Anderson was a project leader with the National Research Council of Canada before joining the Laboratory of Experimental Immunology in 1992.

Research

Cellular and Molecular Studies of Cellular Cytotoxicity

The primary goal of our group is to achieve a more complete understanding of the cellular and molecular mechanisms of natural killer (NK) cell development and function. A large portion of modern cancer research has focused on the ability of the immune system to destroy cancer cells using tumor-specific antibodies and immunomodulatory agents. A better understanding of the mode of NK cell tumor recognition will allow us to design novel antitumor therapies.
The majority of our effort is directed toward the characterization of the murine Ly49 and human KIR families of NK cell receptors for class I MHC. Our lab has determined the organization of the Ly49 gene cluster in 129, BALB/c and NOD mice, demonstrating that Ly49 gene content and functional characteristics are significantly different between inbred mouse strains, analogous to the haplotype differences observed in the human KIR genes.
Our group has discovered a probabilistic transcriptional switch that controls Ly49 gene activation, and we have shown that the separately evolved human KIR gene family uses the same type of switch, indicating that probabilistic switches will likely be involved in many systems where genes are selectively activated in a subset of the cells in a given tissue. This discovery has important implications for the control of stem cell differentiation, and may one day allow us to modify cell fate in differentiating systems such as bone marrow cultures.

Collaborators on this research include Mary Carrington and Dan McVicar, NCI.

This page was last updated on 11/25/2013.